These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35606821)

  • 41. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes.
    Korell F; Berger TR; Maus MV
    Med; 2022 Aug; 3(8):538-564. PubMed ID: 35963235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 44. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
    Zuo YH; Zhao XP; Fan XX
    Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CAR-T cells: the Chinese experience.
    Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H
    Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction.
    Jiang P; Zhang Z; Hu Y; Liang Z; Han Y; Li X; Zeng X; Zhang H; Zhu M; Dong J; Huang H; Qian P
    Leukemia; 2022 Nov; 36(11):2656-2668. PubMed ID: 35962059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic.
    Smirnov S; Mateikovich P; Samochernykh K; Shlyakhto E
    Front Immunol; 2024; 15():1335424. PubMed ID: 38455066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.
    Badieyan ZS; Hoseini SS
    Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):283-288. PubMed ID: 29427174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New CARs on and off the road: challenges and new developments in CAR-T cell therapy.
    Wehrli M; Maus MV
    Curr Opin Pharmacol; 2021 Aug; 59():116-126. PubMed ID: 34198161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
    Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
    Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
    Xiao X; Wang Y; Zou Z; Yang Y; Wang X; Xin X; Tu S; Li Y
    Front Immunol; 2022; 13():954235. PubMed ID: 36091028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation-induced cell death in CAR-T cell therapy.
    Huan T; Chen D; Liu G; Zhang H; Wang X; Wu Z; Wu Y; Xu Q; Yu F
    Hum Cell; 2022 Mar; 35(2):441-447. PubMed ID: 35032297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paving New Roads for CARs.
    Hyrenius-Wittsten A; Roybal KT
    Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The journey of CAR-T therapy in hematological malignancies.
    Lu J; Jiang G
    Mol Cancer; 2022 Oct; 21(1):194. PubMed ID: 36209106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deletion of Cbl-b inhibits CD8
    Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors.
    Labanieh L; Majzner RG; Klysz D; Sotillo E; Fisher CJ; Vilches-Moure JG; Pacheco KZB; Malipatlolla M; Xu P; Hui JH; Murty T; Theruvath J; Mehta N; Yamada-Hunter SA; Weber EW; Heitzeneder S; Parker KR; Satpathy AT; Chang HY; Lin MZ; Cochran JR; Mackall CL
    Cell; 2022 May; 185(10):1745-1763.e22. PubMed ID: 35483375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.